van Heeswijk Rolf P G, Beumont Maria, Kauffman Robert S, Garg Varun
Janssen Infectious Diseases BVBA, Beerse, Belgium.
Antivir Ther. 2013;18(4):553-60. doi: 10.3851/IMP2527. Epub 2013 Jan 23.
HCV infection is a major cause of mortality worldwide. HCV-related deaths also represent a leading cause of mortality in HIV-coinfected individuals. Telaprevir is an NS3/4A protease inhibitor approved for the treatment of chronic HCV genotype 1 infection in adults in combination with pegylated interferon and ribavirin. Telaprevir-based treatment has been shown to increase rates of sustained viral response in HCV genotype-1-monoinfected patients, and studies in HCV-HIV-coinfected patients are ongoing. Drug-drug interactions of telaprevir with antiretroviral drugs were investigated in a series of studies in healthy subjects. This review summarizes the results of interaction studies with low-dose ritonavir, ritonavir-boosted HIV protease inhibitors (atazanavir, darunavir, fosamprenavir and lopinavir), efavirenz, etravirine, rilpivirine, tenofovir disoproxil fumarate and raltegravir.
丙型肝炎病毒（HCV）感染是全球范围内导致死亡的主要原因。与HCV相关的死亡也是合并感染HIV个体死亡的主要原因。特拉匹韦是一种NS3/4A蛋白酶抑制剂，已被批准与聚乙二醇化干扰素和利巴韦林联合用于治疗成人慢性HCV 1型感染。基于特拉匹韦的治疗已显示可提高HCV 1型单一感染患者的持续病毒学应答率，并且针对HCV-HIV合并感染患者的研究正在进行中。在一系列针对健康受试者的研究中，对特拉匹韦与抗逆转录病毒药物之间的药物相互作用进行了调查。本综述总结了与低剂量利托那韦、利托那韦增强的HIV蛋白酶抑制剂（阿扎那韦、达芦那韦、福沙普那韦和洛匹那韦）、依非韦伦、依曲韦林、利匹韦林、替诺福韦酯和拉替拉韦相互作用研究的结果。
